|This article needs additional citations for verification. (June 2007) (Learn how and when to remove this template message)|
Simply doing more
|Marco Gadola (CEO)|
Number of employees
Recently, Straumann entered the fast-growing field of restorative dentistry through the acquisition of etkon, an emerging force in CAD/CAM based tooth replacement. Straumann offers surgical, restorative and regenerative solutions - from bone augmentation and tissue regeneration, through implants and prosthetics, to individualized crowns and bridges.
In collaboration with leading clinics, research institutes and universities, Straumann research and develop implants, instruments and tissue regeneration products for use in tooth replacement solutions or to prevent tooth loss.
The Group manufactures implant system components and instruments in Switzerland and the US and dental tissue regeneration products in Sweden. The restorative products are manufactured in Europe and the US.
Straumann also offer services to the dental profession worldwide, including training and education, which is provided in collaboration with the International Team for Implantology (ITI).
Altogether, Straumann employs approximately 2300 people worldwide and their products and services are available in more than 70 countries through their own distribution subsidiaries and broad network of distribution partners.
The history of the Straumann Group has three distinct eras and spans more than half a century. It began in the Swiss village of Waldenburg in 1954 with the foundation of a research institute bearing the name of its founder, Dr Ing. Reinhardt Straumann.
Between 1954 and 1970, the company specialized in alloys used in timing instruments and in materials testing. Among Straumann’s renowned inventions in this period were special alloys that are still used in watch springs today. A breakthrough in the use of non-corroding alloys for treating bone fractures prompted Dr Fritz Straumann to enter the fields of orthopedics and dental implantology, which began the second phase of the company’s history.
In the small town of Waldenburg, at the foot of the Swiss Jura, Reinhard Straumann founds the "Dr Ing. R. Straumann Research Institute AG".
The Swiss Association for the Study of Internal Fixation (AO/ASIF) is looking for a company that is capable of providing materials for internal fixation implants - Dr H.C. Fritz Straumann, son of the company’s founder, gets in touch.
Between 1970 and 1990, Straumann became a leading manufacturer of osteosynthesis implants. A management buy-out of the osteosynthesis division in 1990 led to the creation of Stratec (subsequently Synthes) as a separate company. 1990 thus marked the beginning of the Straumann Group as it is known today. Thomas Straumann, grandson of the founder, headed the remaining part of the firm, which employed just 25 people focused exclusively on dental implants.
Another major milestone in the company’s history was in 1980 when Straumann established a partnership with the International Team for Implantology forming a symbiosis of research expertise and industrial know-how. The 1980s also marked the company’s geographic expansion, with subsidiaries in Germany (1980) and the US (1989). The following are examples of the groundbreaking achievements that have established Straumann as a leading innovator in implant dentistry:
The first dental implants are developed at the Institut Straumann and undergo successful clinical testing at the University of Berne.
Under the aegis of Dr Fritz Straumann, Waldenburg, and Prof Schroeder, University of Berne, the International Team for Implantology, the ITI, is founded.
After a management buy-out of the internal fixation division, Thomas Straumann focuses the activities of the Institut Straumann AG on the area of implant dentistry.
1998 - Today
In 1998, Straumann Holding AG became a publicly traded company on the Swiss exchange. Through the acquisition of Kuros Therapeutics (2002) and Biora (2003), Straumann entered the promising field of oral tissue regeneration. 1998
The Straumann Holding AG goes public and is listed on the Swiss stock exchange.
With the opening of the production site in Villeret, located in the Berne Jura, and the Technology Center in Waldenburg, new dimensions open up for the international Straumann group.
Straumann acquires Kuros Therapeutics AG and extends its activities into the field of biomaterials.
Straumann acquires the Swedish company Biora, a pioneer in the area of biologically based regeneration of dental tissue.
Straumann AG moves into its new headquarters in Basel.
Straumann acquires Neodent from Brazil and extends its activities into the value Market.
Board of Directors
- Gilbert Achermann - Chairman of the Board
- Dr. H.C. Thomas Straumann - Vice Chairman of the Board, Member Strategy Committee
- Dr. Sebastian Burckhardt - Member Audit Committee, Secretary of the Board
- Dominik Ellenrieder - Member Strategy Committee
- Roland Hess - Chair Audit Committee, Member Strategy Committee
- Ulrich Looser - Chair Strategy Committee, Member HR Committee
- Dr. Beat Lüthi - Member Audit Committee, Member HR Committee
- Stefan Meister - Chair HR Committee
Executive Management Board
- Marco Gadola - President and Chief Executive Officer
- Dr. Peter Hackel - Chief Financial Officer
- Wolfgang Becker - Head Sales Central Europe
- Guillaume Daniellot - Head of Sales Western Europe
- Andy Molnar - Head Sales North America
- Dr. Alexander Ochsner - Head Sales Asia/Pacific
- Frank Hemm - Head Customer Solutions & Education
- Dr. Gerhard Bauer - Head Research, Development & Operations
- Petra Rumpf - Head of Instradent & Strategic Alliances
The product range includes surgical implants and prosthetic components (abutments) that connect the implant with the visible crown of the replacement tooth. Straumann also supply a range of matching precision instruments and handling components.
Complementing the dental implant and restoration system Straumann manufacture products that are used in oral tissue regeneration either to support implant procedures or to help preserve teeth after treatment for periodontal disease.
The Group manufactures implant system components and instruments in Villeret (Switzerland) and Andover (USA), and dental tissue regeneration products in Malmö (Sweden). The tooth restoration products are produced in Europe and the US.
All major components of the Straumann Dental Implant System are currently manufactured at Straumann's factory in Villeret, Switzerland, which produces more than 4.5 million parts a year.
Villeret became operational in 2000. Continued global volume growth made it necessary to expand capacity, and a second production floor was fitted out in 2005. As a result, Villeret now operates two fully independent production lines, one producing surgical products (implants) and the other manufacturing components for the range of implant prosthetics (abutments). Villeret also houses the manufacturing unit for Straumann's third generation implant surface technology SLActive.
The North American headquarters in Andover house Straumann’s first manufacturing unit outside Switzerland and produces implant system components and instruments.
The 7,400-square-meter (80,000-square-foot) production area complements Straumann’s current production unit in Villeret, Switzerland. It is also the home office location for Neodent, the Brazilian value implant Straumann acquired in 2013 as part of its product portfolio.
In contrast to Villeret and Andover, Straumann's production unit in Malmö is devoted primarily to the specialized manufacture of regenerative products.
In June 2003 Straumann acquired the Swedish company Biora, which specialized in the manufacture of the protein-based products for tissue regeneration. The manufacture of Emdogain, an easy to apply protein based gel for use in periodontal disease, is focused in Malmö.